Responsable(s)
Directeur - Pierre Bruhns à partir du 01/11/2014
|
|
Etablissement |
|
INSTITUT PASTEUR - Institut Pasteur ( )
(établissement tutelle à
partir de 2014)
Etablissement référent
|
Adresse
Unité des Anticorps en Thérapie et Pathologie Département d'Immunologie 25-28, rue du Docteur Roux
75724 Paris Cedex 15
|
Contact
courriel :
|
| Site web :
https://research.pasteur.fr/en/team/antibodies-in-therapy-and-pathology/
|
| Taille en ETP (sans compter les stagiaires):
entre 10 et 50.
|
Descriptif :
Antibodies in Therapy & Pathology (INSERM U.1222): from Allergy & Autoimmunity to Cancer Immunotherapy
Antibodies are key effectors of the immune system. They are responsible for disease induction (autoimmunity, allergy) and can be protecting from or facilitating infections and tumors. Antibodies do not exert by themselves, however, biological functions: these are mainly mediated by antibody receptors (FcRs) and complement.
Aims:
- Decipher the role of human antibodies, human antibody receptors (FcRs) and the cells expressing them, and human complement during therapy and in the induction of pathologies.
- Establish high-throughput plasma cell screening, analysis and sorting using droplet microfluidics technologies to understand the antibody response, and demonstrate the pathogenic nature of antibodies in specific diseases (collaboration with ESPCI-ParisTech and HiFiBio)
- Develop ¿humanized¿ mouse models and clinical studies (NASA; PlanA) to understand how antibodies and their effector functions induce/regulate autoimmune (rheumatoid arthritis, thrombocytopenia) and allergic diseases
- Develop immunodeficient mice bearing human FcRs to study therapeutic antibodies against human tumors
To enhance the clinical relevance of our studies in mice, we have generated ¿humanized¿ mouse models expressing human FcRs in the presence of human antibodies, and soon human complement and targets. Our recent focus has been on FcR-expressing myeloid cells, in particular neutrophils and monocytes/macrophages that we extend now to platelets and their interaction with neutrophils, and to mast cells.
Altogether, our research integrating fundamental, clinical and industry-driven approaches, aims at elucidating the role of antibodies, their receptors and the cells expressing them in major disease and therapy models and, hopefully, propose novel therapeutic solutions in antibody-based therapies.
|
| Année de création :
2012
|
| Mission de la structure :
Recherche
|
| Mode de gestion de la structure :
Non renseigné.
|
| SIRET de la structure :
Non renseigné.
|
Classement scientifique ERC
- LS6 : Immunity, Infection and Immunotherapy : The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
|
Domaine scientifique
- 5 : Biologie, médecine et santé 2014 0
|
Ecole(s) doctorale(s) de rattachement
Non renseigné
|
Rattachée au(x) programme(s) LOLF suivant(s):
Non renseigné
|
Rattachée au(x) thème(s) de recherche suivant(s):
Anticorps, Fc récepteurs, allergie, autoimmunité, microfluidique, immunothérapie;
|
Liens avec d'autres structures :
Participe à :
-
Unité propre 200621930R - Département d'Immunologie
(lien non exclusif)
-
Unité mixte 201622813G - IMMUNITE HUMORALE
(lien non exclusif)
|
Site ESR :
Aucun.
|
Fiche mise à jour par Marie-Laure ROSSO le 31/05/2022 à 14:37
|
